5.5-Dichlor-1-pentanol | 32905-51-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5.5-Dichlor-1-pentanol
• 英文别名: 5,5-dichloro-pentan-1-ol；5,5-Dichloropentan-1-ol
• CAS: 32905-51-4
• 化学式: C₅H₁₀Cl₂O
• 分子量: 157.04
• InChiKey: BSQPDKORZCMDBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5.5-Dichlor-1-pentanol 在 硫酸 、 氢溴酸 作用下， 生成 5-bromo-1,1-dichloro-pentane
  参考文献：
  名称：

  Action of magnesium on polyhaloalkanes and polyhaloalkenes and synthesis of 5, 5-dichloropentaneboronic acid

  摘要：

  DOI：

  10.1007/bf00862200
• 作为产物：
  描述：

  5,5-Dichlorpentanboronsaeure 在 双氧水 作用下， 生成 5.5-Dichlor-1-pentanol
  参考文献：
  名称：

  Action of magnesium on polyhaloalkanes and polyhaloalkenes and synthesis of 5, 5-dichloropentaneboronic acid

  摘要：

  DOI：

  10.1007/bf00862200

文献信息

• Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
  申请人：Cowart D. Marlon

  公开号：US20060172995A1

  公开（公告）日：2006-08-03

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B, are as described in the specification.

  本发明涉及使用公式(I)化合物的用途，用于治疗性功能障碍，以及包含用于治疗性功能障碍的公式(I)化合物的组合物，其中A、L、D和B如说明书中所述。
• METHOD FOR PRODUCING CYCLIC CARBONATE
  申请人：NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY

  公开号：US20160145234A1

  公开（公告）日：2016-05-26

  Provided is a method for producing a cyclic carbonate obtained by reacting epoxide and carbon dioxide, the method being capable of efficiently producing a cyclic carbonate at a high conversion rate and a high yield, in which degradation of the catalyst over time is suppressed and catalytic activity hardly decreases. A method for producing a cyclic carbonate by reacting epoxide and carbon dioxide in the presence of a quaternary onium salt selected from the group consisting of a quaternary ammonium salt having a halogenated anion as a counter ion and a quaternary phosphonium salt having a halogenated anion as a counter ion, or in the presence of a solid catalyst obtained by immobilizing the quaternary onium salt onto a carrier, wherein an organohalogen compound containing at least one halogen atom in one molecule is added to the reaction system.

  提供了一种生产环状碳酸酯的方法，该方法通过反应环氧化物和二氧化碳获得，能够高效地以高转化率和高产率生产环状碳酸酯，同时抑制催化剂随时间降解并且催化活性几乎不会下降。在存在从属于具有卤素阴离子作为对离子的季铵盐和具有卤素阴离子作为对离子的季膦盐中选择的季铵盐，或者存在通过将季铵盐固定在载体上而获得的固体催化剂的情况下，通过在反应体系中添加含有至少一个卤素原子的有机卤素化合物来生产环状碳酸酯的方法。
• Ring opening alkylation of cyclic ethers with α-halogenoalkyllithiums in the presence of boron trifluoride–diethyl ether
  作者：Toshiro Imai、Shinya Nishida、Takashi Tsuji

  DOI：10.1039/c39940002353

  日期：——

  It is demonstrated for the first time that α-halogenoalkyllithium reagents can be utilized for ring opening alkylation of various oxiranes, oxtane and oxolane (THF) in the presence of boron trifluoride–diethyl ether at low temperatures.

  首次证明，α-卤代烷基锂试剂可在低温下在三氟化硼-乙醚存在下用于各种环氧乙烷，环氧乙烷和环氧丙烷（THF）的开环烷基化。
• Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction
  申请人：Cowart D. Marlon

  公开号：US20070265249A1

  公开（公告）日：2007-11-15

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B 1 are as described in the specification.

  本发明涉及使用式（I）化合物治疗性功能障碍以及含有式（I）化合物的组合物治疗性功能障碍，其中A、L、D和B1如说明书所述。
• Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same
  申请人：Aoki Kazumasa

  公开号：US20120220593A1

  公开（公告）日：2012-08-30

  A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R 1 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R 2 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; and X is, for example, a hydroxyl group or a C 1 -C 6 alkoxy group].

  一种制药组合物，包括具有式（I）或其药理学上可接受的盐作为活性成分的化合物：[其中，R1是例如C6-C10芳基基团，该基团可以被选自取代基α的一个或多个基团替代；R2是例如C6-C10芳基基团，该基团可以被选自取代基α的一个或多个基团替代；X是例如羟基或C1-C6烷氧基。]